Predictive method for assessing the efficacy of mosunetuzumab and epcoritamab

Clinical investigation of immunotherapeutic approaches for follicular lymphoma - Clinical investigation of immunotherapeutic approaches

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058234

Enrollment

Registered

2025-06-27

Start date

2025-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

follicular lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically diagnosed as follicular lymphoma. Scheduled to undergo mosunetuzumab or epcoritamab therapy. Provided informed consent.

Exclusion criteria

Exclusion criteria: Deemed inappropriate by the attending physician.

Design outcomes

Primary

Measure	Time frame
The correlation between peripheral T cell cytotoxicity and the therapeutic efficacy of mosunetuzumab or epcoritamab.	—

Secondary

Measure	Time frame
The efficacy of tetracyclines in enhancing peripheral T cell cytotoxicity.	—

Countries

Japan

Contacts

Public ContactKota Iwahori

Osaka International Cancer Institute Department of Cancer Immunotherapy

kota.iwahori@oici.jp+81-6-6945-1181

Outcome results